The new immunosuppressive era

A. I. Lo Monte, G. Ciancio*, G. Burke, D. Roth, J. Miller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Immunosuppression, although necessary to enable the graft to escape the consequence of immune surveillance carries some risks for the patients. There is an associated increase in neoplasm, opportunistic infections, and end-organ toxicity. In addition, even with excellent patient compliance, rejection (acute and chronic) remain a major limitation that contributes to the loss or decrease in the Junction of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue graft from cyclosporine-resistant. Most of the immunosuppressive agents in use today are direct at the T lymphocyte, non-specifically inhibiting T-cell activation and proliferation. The authors described here an update of these new immunosuppressive agents and new strategies used in solid organ transplantation.

Original languageEnglish (US)
Pages (from-to)1-19
Number of pages19
JournalAnnali Italiani di Chirurgia
Issue number1
StatePublished - Jan 1 1999


  • Bone marrow
  • Chimerism
  • Immunosuppressive agents
  • Organ transplantation
  • Rejection
  • Tolerance

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'The new immunosuppressive era'. Together they form a unique fingerprint.

Cite this